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The Ubiquitous Glucose Transporter GLUT-1
Is a Receptor for HTLV
diseases has been established and the identity of the
receptor(s) for HTLV-1 and HTLV-2 Env has remained
elusive.
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to play a role in HTLV Env-mediated syncytia formationF-34293 Montpellier Cedex 5
France (Daenke et al., 1999; Hildreth et al., 1997) and in enhanc-
ing virus adsorption and infection (Pinon et al., 2003).
Nevertheless, HTLV Env-dependent cell membrane fu-
sion and syncytia formation appear to be distinct from
receptor binding per se (Daenke and Booth, 2000;Summary
Denesvre et al., 1996; Kim et al., 2000, 2003b). The
search for the HTLV Env receptor has been hindered inThe human T cell leukemia virus (HTLV) is associated
part by its ubiquitous presence (Jassal et al., 2001; Kimwith leukemia and neurological syndromes. The phys-
et al., 2003b; Sutton and Littman, 1996). Additionally,iopathological effects of HTLV envelopes are unclear
the induction of rampant syncytium formation in celland the identity of the receptor, present on all verte-
culture upon expression of HTLV Env has preventedbrate cell lines, has been elusive. We show that the
its efficient and persistent expression. Based on ourreceptor binding domains of both HTLV-1 and -2 enve-
observation that the HTLV Env amino-terminal domainlope glycoproteins inhibit glucose transport by inter-
shares striking structural and functional homology withacting with GLUT-1, the ubiquitous vertebrate glucose
that of murine leukemia viruses (MLV) (Battini et al.,transporter. Receptor binding and HTLV envelope-
1995; Kim et al., 2000, 2003a), we defined the HTLV Envdriven infection are selectively inhibited when glucose
receptor binding domain (RBD) and derived HTLV Env-transport or GLUT-1 expression are blocked by cyto-
based tools that overcome the problem of syncytia for-chalasin B or siRNAs, respectively. Furthermore, ec-
mation (Kim et al., 2000, 2003b). We were thus able totopic expression of GLUT-1, but not the related trans-
follow specific interactions between the Env RBD andporter GLUT-3, restores HTLV infection abrogated by
the HTLV receptor. We found that the HTLV receptor iseither GLUT-1 siRNAs or interfering HTLV envelope
not expressed on the surface of quiescent T lympho-glycoproteins. Therefore, GLUT-1 is a receptor for
cytes, the major HTLV reservoir in vivo, but is inducedHTLV. Perturbations in glucose metabolism resulting
following T cell activation (Manel et al., 2003).from interactions of HTLV envelope glycoproteins with
Here, we describe striking metabolic alterations inGLUT-1 are likely to contribute to HTLV-associated
cells expressing HTLV envelopes as well as truncateddisorders.
HTLV receptor binding domains. These alterations are
independent of syncytia formation and are character-Introduction
ized by a defect in the acidification of the cell culture
medium associated with decreased extracellular lactateThe human T cell leukemia virus (HTLV) type 1 and 2 are
production and diminished glucose uptake and con-present in all areas of the world as endemic or sporadic
sumption. These observations, as well as the knowledgeinfectious agents (Slattery et al., 1999). The etiological
that Env receptors for the related MLV and most gamma-role of HTLV-1 in adult T cell leukemia (ATL) and tropi-
retroviruses belong to the family of multimembrane-cal spastic paraparesis/HTLV-associated myelopathy
spanning transporters (Overbaugh et al., 2001), prompted(TSP/HAM) has been well established (Gessain et al.,
us to test ubiquitous lactate and glucose transport-1985; Osame et al., 1986; Poiesz et al., 1980; Yoshida
associated molecules that are upregulated on activatedet al., 1982). The apparently restricted tropism of HTLV
T cells, as receptors for HTLV Env. We show that theto T lymphocytes in infected patients (Cavrois et al.,
ubiquitous glucose transporter GLUT-1 is a specific1996; Hanon et al., 2000) contrasts with the ability of
component of the HTLV receptor and plays an essentialthe viral-encoded envelope glycoprotein (Env) to bind
role in HTLV-envelope mediated infection. Our observa-to and direct entry into all vertebrate cell types tested
tion that interaction of GLUT-1 with the entire HTLV-1in vitro (Kim et al., 2003b; Sutton and Littman, 1996;
and HTLV-2 envelopes as well as truncated HTLV-1 andTrejo and Ratner, 2000). Retroviral infections depend on
HTLV-2 RBD alters glucose metabolism provides newearly interactions between Env and cellular receptors.
leads regarding the mechanisms implicated in HTLV-Identification of cellular receptors and coreceptors for
associated physiopathological disorders.other retroviral envelopes have helped to elucidate cer-
tain aspects of retrovirus physiopathology as well as
their transmission and spreading within organisms and Results
populations (Overbaugh et al., 2001). However, no clear
association between HTLV Env and HTLV-associated HTLV Envelopes and Lactate Metabolism
Cell proliferation in standard culture media is accompa-
nied by acidification of the milieu that translates into a*Correspondence: sitbon@igm.cnrs-mop.fr (M.S.), battini@igm.
color change from red to yellow tones in the presencecnrs-mop.fr (J.-L.B.)
1These authors contributed equally to this work. of the phenol-red pH indicator. Upon transfection of
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Figure 1. HTLV Envelope-Receptor Binding Alters Extracellular Lactate Production and Glucose Transport
(A) Medium acidification and syncytia formation (Giemsa staining) in 293T cells one day post-transfection with control DNA (pCDNA) or Env
expression vectors, including syncytial wild-type HTLV-1 Env and HTLV-2 Env, a non-syncytial chimeric HTLV/MLV Env harboring the HTLV
receptor binding domain (H183FEnv), and a syncytial amphotropic-MLV Env (A-MLV R). Yellow medium indicates normal acidification during
cell culture.
(B) Extracellular lactate production in the culture medium of 293T cells was measured two days following transfection with control DNA
(pCDNA), with expression vectors containing Friend-MLV (F-MLV) Env, chimeric H183FEnv, HTLV-1 (H1RBD), or amphotropic MLV RBD (ARBD).
Mean extracellular lactate production normalized to cellular protein content of triplicate samples is shown.
(C) Binding of rFc-tagged H1RBD, D106A, and Y114A H1RBD mutants on 293T cells was monitored by FACS analysis following incubation with
a FITC-conjugated anti-rabbit IgG antibody.
(D) Extracellular lactate production in the medium of 293T cells one day post-transfection with an irrelevant DNA (pCDNA), H1RBD, or the D106A
and Y114A H1RBD mutants. Data are representative of three independent experiments. The secretion or presence of HTLV Env mutants in the
293T-transfected culture medium was monitored by immunoblotting with a peroxidase-conjugated anti-rabbit IgG antibody.
(E) Extracellular glucose in the culture medium of 293T cells was measured two days following transfection with pCDNA, F-MLV Env, H183FEnv,
H1RBD, or ARBD. This measure was used to calculate mean glucose consumption after normalization to cellular protein content.
(F) 2-deoxy[1-3H]glucose and [U-14C]fructose uptake following either transfection of 293T cells with control DNA (pCDNA), H1RBD, H2RBD, or ARBD
expression vectors, or treatment with the cytochalasin B and phloretin glucose transporter inhibitors (pCDNAinhibitors). Data are the means
of triplicate measures and are representative of two to three independent experiments.
293T cells with either highly syncytial HTLV-1 and HTLV-2 pressed in cells that are resistant to HTLV-Env mediated
syncytia formation (NIH3T3 TK cells) (Kim et al., 2003b)envelopes, or a non-syncytial chimeric envelope that
harbors the HTLV-1 RBD in an MLV Env backbone (not shown).
The acidification of cell culture media is associated(H183FEnv), culture medium did not readily become
acidic, and harbored red tones for several days post- with the extracellular accumulation of lactate (Warburg,
1956). Lactate is the major byproduct of anaerobic gly-transfection (Figure 1A). Moreover, expression of trun-
cated soluble HTLV RBD proteins fused with either colysis in vitro and its excretion is mediated by an H/
lactate symporter (Halestrap and Price, 1999). We moni-EGFP, an influenza hemagglutinin peptide tag (HA), or
a rabbit immunoglobulin fragment (rFc) also inhibited tored lactate content in culture supernatants following
transfection of various retroviral envelopes and RBD.medium acidification (not shown). In contrast, envelope
constructs that lacked HTLV RBD did not have this ef- Extracellular lactate production was consistently 3-fold
lower in H183FEnv- and HTLV RBD-transfected cells thanfect, including different MLV group envelopes, feline,
porcine, lentiviral, and Jaagsiekte retroviral Env, as well in control- or MLV Env-transfected cells (Figure 1B).
This difference was detected as early as 4 hr after theas VSVG and Ebola glycoproteins (not shown). Syncy-
tium formation was not in itself responsible for this ef- addition of fresh media (not shown). Moreover, this de-
crease in extracellular lactate production after HTLVfect; medium acidification was observed in cells ex-
pressing a syncytial amphotropic-MLV (A-MLV R) Env RBD transfection was DNA dose dependent (not shown).
To examine whether there is a direct relationship be-(Figure 1A), and was blocked when HTLV Env was ex-
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tween binding of the HTLV envelope receptor and the
subsequent diminution in extracellular lactate produc-
tion and acidification, we used HTLV RBD mutants with
impaired receptor binding capacities. For this purpose,
mutations resulting in single alanine substitutions were
introduced in H1RBD, at either the D106 or Y114 positions,
both of which are highly conserved among primate
T-lymphotropic viruses (F.J.K., unpublished observa-
tions). D106A and Y114A RBD mutants exhibited signifi-
cantly reduced (D106A) or non-detectable (Y114A) bind-
ing to the HTLV receptor as monitored by FACS analysis
(Figure 1C) and did not lead to detectable infection (not
shown). Moreover, extracellular lactate accumulation
was not reduced in cells expressing the non binding
Y114A RBD mutant and was only partially reduced in
cells harboring the D106A RBD, although both D106A
and Y114A RBD mutants were expressed and secreted
as efficiently as the wild-type H1RBD (Figure 1D). Similar
results were obtained with H2RBD harboring the same
allelic mutations (not shown), following transfection of
these mutants in HeLa cells. Therefore, perturbations in
lactate metabolism directly correlated with binding of
HTLV RBD to the HTLV receptor.
Extracellular lactate accumulates in cell cultures follow-
ing its transport across cellular membranes by the multi-
membrane-spanning MCT1 monocarboxylate transporter
(Garcia et al., 1994). Because HTLV and MLV envelopes
share a common modular organization (Kim et al., 2000,
2003a) and the receptors for MLV Env are multimem-
brane-spanning metabolite transporters (Overbaugh et
al., 2001), we assessed whether the HTLV RBD bound
to MCT1. Moreover, expression of the MCT1 chaperone
Figure 2. Expression of the HTLV Receptor on Glucose-Starved CellCD147 (Kirk et al., 2000) increases during T cell activa-
Lines and Primary Cellstion (Kasinrerk et al., 1992), a characteristic of the HTLV
(A) Expression of the HTLV and amphotropic-MLV receptors onreceptor (Manel et al., 2003; Nath et al., 2003). Neverthe-
293T and Jurkat T cells cultured overnight in the presence (1 g/l) orless, separate and combined overexpression of MCT1
absence of glucose was monitored by binding of H1RBD and ARBD, re-and CD147 did not result in increased H1RBD binding (not spectively.
shown), arguing against a role for these molecules as (B) Expression of the HTLV and amphotropic-MLV receptors on the
receptors for HTLV Env. surface of freshly isolated human and murine erythrocytes, and
primary human hepatocytes was monitored by binding of H1RBD and
ARBD, respectively. Binding of the HTLV envelope RBD is shown inHTLV Envelopes Alter Glucose Metabolism
filled histograms, ARBD binding is shown in dotted histograms, andIn addition to a decrease in extracellular lactate accumu- control immunofluorescence is shown in solid line histograms.
lation, expression of the HTLV RBD also led to decreased
intracellular lactate content (not shown), indicative of
metabolic alterations upstream of lactate transport. In ble to the decrease observed when glucose uptake was
inhibited by cytochalasin B and phloretin. The envelope-cell cultures, lactate production results from the degra-
dation of glucose during anaerobic glycolysis. There- mediated inhibition was specific to HTLV, since the
A-MLV RBD (ARBD) control envelope had only a minorfore, we assessed whether the decreased accumulation
of lactate observed upon expression of HTLV RBD was effect on glucose uptake. Moreover, the inhibitory effect
of HTLV envelopes was specific to glucose uptake, sincelinked to glucose metabolism. We measured glucose
consumption as an indicator of the rate of glycolysis. 3-O-methylglucose transport was similarly inhibited (not
shown) whereas fructose uptake was not altered by theGlucose consumption of cells expressing an HTLV RBD
within the context of the H183FEnv entire envelope or the presence of either HTLV-1 or HTLV-2 RBD (Figure 1F).
The decrease in glucose transport was likely due totagged H1RBD was significantly decreased as compared
to that of control cells (Figure 1E) and this defect was the steady state expression of the HTLV RBD following
transfection, as the level of the secreted RBD was insuf-detected as early as 8 hr post-transfection (not shown).
Notably, the transfection efficiencies in the experiments ficient to modulate glucose metabolism.
We next evaluated the effect of glucose deprivationranged from 80%–95% (not shown).
We found that this decrease in glucose consumption on the availability of the HTLV receptor in both adherent
293T cells and suspension Jurkat T cells. After overnightcorrelated with a decrease in glucose transport across
the cellular membrane. Transfection of either HTLV-1 or culture of cells in the absence of glucose, binding of
H1RBD was surprisingly increased by 2-fold in both cellHTLV-2 RBD resulted in an approximately 4-fold de-
crease in 2-deoxyglucose uptake (Figure 1F), compara- types (Figure 2A). This effect of glucose deprivation was
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specific to HTLV as ARBD binding was only marginally below). However, unlike GLUT-1, overexpression of
GLUT-3 did not increase H1RBD and H2RBD binding (Figurealtered under the same conditions (Figure 2A). This phe-
nomenon is reminiscent of a general metabolite trans- 3A). These data demonstrate that increased HTLV RBD
binding is specific to GLUT-1 expression and not anport feedback loop, whereby transporter availability at
the cell surface increases upon substrate starvation. indirect consequence of increased glucose uptake. To
confirm that increased H1RBD binding was directly due
to those cells that overexpressed GLUT-1, we derivedGLUT-1 Expression Parallels HTLV RBD Binding
DsRed2 fluorochrome-tagged GLUT-1 and GLUT-3 ex-Inhibition of glucose consumption via binding of the
pression vectors to unequivocally identify GLUT-over-HTLV RBD to a glucose transporter is compatible with
expressing cells. In this context, we found that thosethe metabolic effects described above. Upon evaluation
cells overexpressing DsRed2-tagged GLUT-1 displayedof the different glucose transporter candidates, GLUT-1
significantly increased H1RBD binding, as demonstratedwas the only one to present all the known properties
by FACS analysis (Figure 3B). H1RBD binding was notof the HTLV receptor. Indeed, GLUT-1 expression is
altered in cells overexpressing the tagged-GLUT-3.increased upon glucose deprivation and is involved in
A direct interaction between GLUT-1 and HTLV enve-glucose transport in all vertebrates (Mueckler et al.,
lopes was demonstrated by coimmunoprecipitation of1985). Furthermore, GLUT-1 is not expressed on quies-
H1RBD and GLUT-1. As shown in Figure 4, GLUT-1 wascent primary T cells and its expression is induced upon
detected upon immunoprecipitation of H1RBD-rFc withT cell activation (Chakrabarti et al., 1994; Rathmell et
anti-rabbit-IgG-coated beads. The coimmunoprecipita-al., 2000) with kinetics that are strikingly similar to what
tion of GLUT-1 with the H1RBD Y114A receptor bindingwe and others have reported for the HTLV receptor (Ma-
defective mutant was dramatically diminished. No coim-nel et al., 2003; Nath et al., 2003). Since human, but not
munoprecipitation was observed in the absence ofmurine, erythrocytes have been described to exhibit the
HTLV RBD.highest concentration of GLUT-1 (Mantych et al., 1991;
Mueckler, 1994), we compared HTLV receptor availabil-
ity on freshly isolated human and murine red blood cells. GLUT-1 Mediates HTLV Infection
Binding of H1RBD to human erythrocytes was remarkably As demonstrated above, HTLV envelopes physically as-
efficient, reaching levels higher than those observed on sociate with GLUT-1 and this interaction modulates glu-
any other tested cell type (Figure 2B and not shown). cose metabolism. To determine whether this interaction
In marked contrast, no significant H1RBD binding was is essential for infection, it would have been opportune
detected on murine erythrocytes although comparably to use GLUT-1-deficient cell lines. However, since there
low levels of ARBD binding were observed on murine and are no GLUT-1 null cell lines and since quiescent primary
human erythrocytes. Similarly, primary human hepato- cells lacking GLUT-1 are not amenable to HTLV infection
cytes which do not express GLUT-1 (Mueckler, 1994) assays, we developed three different models of HTLV
did not bind H1RBD, while ARBD binding on these cells was envelope-driven infection in which either receptor avail-
readily detected (Figure 2B). Thus, the expression of ability or GLUT-1 expression were limiting.
GLUT-1 parallels that of the HTLV receptor. In the first model, we monitored HTLV envelope-driven
infection in the presence of cytochalasin B which inhibits
glucose transport (Kasahara and Hinkle, 1977) andHTLV Envelopes Bind GLUT-1
In order to directly test the ability of HTLV envelopes to which we found to inhibit HTLV RBD binding. Indeed,
treatment of Jurkat T cells with cytochalasin B dramati-bind GLUT-1, we derived a tagged GLUT-1 expression
vector and overexpressed this protein in 293T cells. cally inhibited binding of H1RBD, whereas binding of ARBD
remained unchanged (Figure 5A). To determine whetherBinding of both H1RBD and H2RBD were dramatically in-
creased upon GLUT-1 overexpression (Figure 3A). This this effect was due to the role of cytochalasin B as a
ligand for GLUT-1 or, alternatively, was indirectly due tointeraction required a functional HTLV RBD as binding
of the D102A HTLV-2 mutant did not increase following its indirect effects on microfilaments, cells were treated
with the related molecule cytochalasin D. This latteroverexpression of GLUT-1 (Figure 3A). Moreover, this
interaction was specific to GLUT-1, since H1RBD and molecule, which is not a ligand of GLUT-1, led to a
low-level, nonspecific decrease in both HTLV and ARBDH2RBD binding remained at background levels upon over-
expression of the A-MLV envelope receptor, the inor- binding (see Supplemental Data at above URL). Thus,
these data suggest that the cytochalasin B-mediatedganic phosphate transporter PiT-2 (Miller et al., 1994;
van Zeijl et al., 1994). However, as expected, binding of inhibition of HTLV RBD binding is largely due to its inter-
action with GLUT-1 and not to an impact on actin micro-ARBD was specifically increased upon transfection of PiT-2,
but remained unchanged after GLUT-1 overexpression filaments.
To determine whether the cytochalasin B-mediated(Figure 3A).
The specificity of the interaction between GLUT-1 and decrease in receptor availability would translate into an
effect on HTLV envelope-driven infection, control andHTLV RBD was further confirmed by experiments using
GLUT-3, the closest isoform to GLUT-1 whose glucose cytochalasin B-treated cells were infected with virions
harboring either the HTLV or A-MLV envelopes (Figuretransport kinetics are similar to that of GLUT-1 (Asano
et al., 1992; Joost and Thorens, 2001). GLUT-3 is ex- 5B). A 75% inhibition of HTLV envelope-driven infection
was observed after cytochalasin B treatment. In con-pressed at similar levels as GLUT-1 (See Supplemental
Data available at http://www.cell.com/cgi/content/full/ trast, A-MLV envelope-driven infection was not reduced,
but was in fact increased.115/4/449/DC1), and like GLUT-1, alleviates the block
in glucose metabolism induced by the HTLV RBD (see In the second model, HTLV receptor availability was
The Glucose Transporter Glut-1 Is an HTLV Receptor
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Figure 3. HTLV Envelope-Receptor Binding Increases in GLUT-1 Overexpressing Cells
(A) Binding of H1RBD, H2RBD, H2RBD D102A mutant, and ARBD to control 293T cells or 293T cells overexpressing either GLUT-1, GLUT-3, or PiT-2.
Intrinsic fluorescence (solid line histograms), wild-type RBD binding (filled histograms), and mutant D102A binding (dotted lines histograms)
are shown.
(B) Correlation between GLUT-1 expression and HTLV RBD binding in individual cells. FACS analyses of H2RBD-EGFP binding to 293T cells
transfected with control DNA (pCDNA), GLUT-1-DsRed2, or GLUT-3-DsRed2 expression vectors are shown. Quadrants were drawn to separate
cells with basal HTLV RBD binding from cells with high binding. The percentage of cells in each quadrant is indicated.
specifically limited by the intracellular expression of an RBD binding (Figure 7A) and a 75% inhibition of HTLV
envelope-mediated infection (Figure 7B). As observedinterfering HTLV envelope RBD (H2RBD). In these condi-
tions, both extracellular binding of HTLV envelope (Figure in the receptor interference experiments, overexpres-
sion of GLUT-1, but not GLUT-3, restored HTLV RBD6A) and infection by HTLV envelope-harboring virions
(Figure 6B) were dramatically reduced. Overexpression binding and HTLV envelope-mediated infection (Figures
7A and 7B). The effect of the GLUT-1 siRNAs on HTLVof GLUT-1 in these cells rescued HTLV envelope-medi-
ated binding and infection. Although overexpression of envelope-driven infection was not due to metabolic pet-
urbations per se as both GLUT-1 and GLUT-3 overex-GLUT-3 in these cells reversed defects in lactate and
glucose metabolism (Figure 6C and not shown), HTLV pression reestablished glucose transport and lactate
production (Figure 7C and data not shown). Further-envelope binding and viral titers remained significantly
reduced. Expression of the interfering H2RBD was equiva- more, GLUT-1 siRNAs did not inhibit A-MLV envelope-
mediated binding and infection. Down-modulation oflent in all conditions of glucose transporter overexpres-
sion (Figure 6D). These results confirmed the specific GLUT-1 by siRNAs, and overexpression of ectopic
GLUT-1 following transfection were directly verified inrelationship between HTLV receptor availability and
GLUT-1 expression. these different cell culture conditions by immunoblotting
with an anti-GLUT-1 polyclonal antibody (Figure 7D).In the third model, we used siRNAs directed against
the GLUT-1 3UTR to specifically down-modulate en- Altogether, these data demonstrate that HTLV envelope-
mediated viral entry occurs through a direct interactiondogenous GLUT-1 expression. Transfection of those
GLUT-1 siRNAs led to a concomitant decrease in HTLV with GLUT-1.
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Figure 4. GLUT-1 Physically Associates with the HTLV Envelope
Immunoprecipitation of HA-tagged GLUT-1 from 293T cells trans-
fected with expression vectors carrying control DNA, GLUT-1 alone,
or a combination of GLUT-1 with either wild-type H1RBD or the Y114A
H1RBD mutant. Immunoprecipitations were performed using anti-rab-
bit-IgG beads and blots were probed with an anti-HA antibody. Total
cell extracts were blotted using a monoclonal anti-HTLV envelope
antibody (1C11) and an anti-HA antibody to monitor HTLV RBD and
GLUT-1 levels, respectively.
Discussion
Here we show that the HTLV-1 and -2 receptor binding
domains physically associate with the glucose trans-
porter GLUT-1. This interaction strongly inhibited glu-
cose uptake and consumption, leading to decreased Figure 5. Cytochalasin B Inhibits HTLV Envelope Binding and In-
lactate production and a drop in the acidification of the fection
extracellular milieu. This effect was specific as HTLV-1 and (A) H1RBD and ARBD binding were monitored on Jurkat cells pretreated
2 envelopes with mutations that interfered with receptor with or without 20 M of the GLUT-1 inhibitor cytochalasin B.
(B) Relative infectious titers of virions pseudotyped with eitherbinding did not block glucose consumption (not shown).
HTLV-2 (shaded) or A-MLV (open) envelopes were assessed in con-There was a rapid increase in HTLV envelope binding
trol and cytochalasin B-treated HeLa cells. Relative infectious titersupon glucose starvation, highlighting a nutrient-sensing
were calculated from input virions ranging from 10 to 80 PFU per
negative feedback loop between glucose availability well for both HTLV-2 and A-MLV.
and cell surface HTLV receptor expression. In this con-
text, we explored whether GLUT-1, the ubiquitous glu-
cose transporter, was a receptor for HTLV Env-mediated HTLV RBD binding is increased upon overexpression of
GLUT-1 but not GLUT-3; and GLUT-1 coimmunoprecipi-viral entry. Because antibodies that reliably interact with
all the glycosylated forms of GLUT-1 have been raised tates with H1RBD. Moreover, as we previously demon-
strated for the HTLV receptor (Manel et al., 2003),against internal determinants, they could not be used
to inhibit HTLV Env-mediated viral entry (M. Mueckler, GLUT-1 is not expressed on resting T lymphocytes
whereas the GLUT 2-4 isoforms are present (Chakrabartipersonal communication). Nevertheless, extensive evi-
dence converged to identify GLUT-1 as the receptor for et al., 1994; Korgun et al., 2002), and GLUT-1 is induced
upon immunological (Frauwirth et al., 2002; Yu et al.,HTLV envelope-mediated binding and infection: HTLV
envelopes bind all vertebrate cell lines but not insect 2003) or pharmacological (Chakrabarti et al., 1994) acti-
vation. Finally, GLUT-1 overexpression specifically re-cells and GLUT-1 orthologs are conserved among verte-
brates but are highly divergent between vertebrates and stores HTLV envelope-mediated infection after receptor
blocking with either an interfering HTLV envelope orinsects (Escher and Rasmuson-Lestander, 1999); high-
est binding of HTLV RBD is observed on human erythro- GLUT-1 siRNAs. GLUT-1 is thus a new member of the
multimembrane spanning metabolite transporter familycytes, where GLUT-1 is the major glucose transporter
isoform (Concha et al., 1997); HTLV RBD binding is not known to serve as receptors for retroviral envelopes.
Interestingly, until now, all envelopes that recognizedetected on human primary hepatocytes and murine
erythrocytes where GLUT-1 is known to be only mini- such receptors have been shown to be encoded by
retroviruses that have a “simple” genetic organization,mally expressed (Mantych et al., 1991; Mueckler, 1994);
The Glucose Transporter Glut-1 Is an HTLV Receptor
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Figure 6. RBD Interference to HTLV Envelope Binding and Infection Is Alleviated by GLUT-1
293T cells were transfected with an irrelevant or interfering HTLV RBD expression vector, alone or together with GLUT-1 or GLUT-3 expression
vectors. Transfected cells were assayed for (A) H1RBD and ARBD binding. Specific binding and intrinsic fluorescence are indicated by filled and
solid histograms, respectively. (B) Relative infection titers of virions pseudotyped with either HTLV-2 (shaded) or A-MLV (open) envelopes.
Input virions ranged from 50 to 300 PFU per well. (C) Extracellular lactate accumulation in 293T cell culture medium one day after transfection.
(D) HTLV RBD (H2RBD) expression was monitored by immunoblotting of total protein extracts with an anti-rabbit-IgG antibody.
such as MLV, feline leukemia viruses, porcine endoge- genomes, the HTLV and MLV envelopes share a similar
modular organization with highly conserved amino acidnous retrovirus, and the gibbon ape leukemia virus (Over-
baugh et al., 2001; Tailor et al., 2003), whereas HTLV is motifs in their respective receptor binding domains (Kim
et al., 2000, 2003a).a “complex” retrovirus that codes for several additional
regulatory proteins. However, we have shown that in Cell-to-cell contact and oriented cytoskeleton move-
ments appear to be required for HTLV transmission (Iga-contrast to the wide phylogenetic divergence of their
Cell
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Figure 7. GLUT-1 Is Required for HTLV Enve-
lope Binding and Infection
293T cells were transfected with a mixture of
three GLUT-1 specific siRNAs or irrelevant
siRNAs in combination with either an empty,
a GLUT-1, or a GLUT-3 expression vector.
Transfected cells were assayed for (A) H1RBD
and ARBD binding. Specific binding and intrin-
sic fluorescence are indicated by filled and
solid-line histograms, respectively. (B) Rela-
tive infection titers of virions pseudotyped
with either HTLV-2 (shaded) or A-MLV (open)
envelopes. Input virions ranged from 50 to
400 PFU per well. (C) 2-deoxy[1-3H]glucose
uptake. Uptake was measured in cells trans-
fected with the GLUT-1 siRNAs and GLUT-1
and GLUT-3 expression vectors. Cells incu-
bated with cytochalasin B and phloretin in-
hibitors were used as controls for glucose
transport inhibition. (D) Endogenous and ec-
topic GLUT-1 expression; expression was
monitored by immunoblotting total protein
extracts with an anti-GLUT-1 antibody. Equiva-
lent protein loading was confirmed by immu-
noblotting with an anti-actin antibody.
kura et al., 2003). A role for envelope and receptor inter- immature thymocytes (Feuer et al., 1996; Yu et al., 2003).
The ability of circulating erythrocytes to dock HTLV, asactions in these processes has been suggested (Derse
and Heidecker, 2003). In agreement with these observa- shown here, might provide a means of distributing HTLV
to such tissues, provided that they are not readily elimi-tions, we found that the HTLV receptor, despite pancel-
lular expression, is specifically concentrated to mobile nated by the reticuloendothelial system. Elucidation of
GLUT-1 cell surface recycling upon HTLV envelopemembrane regions and cell-to-cell contact areas (Sup-
plemental Data). This suggests that the HTLV envelope binding to different cell types, including murine and hu-
man erythrocytes, may offer further clues to the in vivoreceptor associates with the cytoskeleton. Indeed, a
cytoplasmic binding partner of GLUT-1, GLUT1CBP, distribution of HTLV during infection.
The identification of GLUT-1 as a receptor for HTLVwhich encodes a PDZ domain, has been reported to link
GLUT-1 to the cytoskeleton (Bunn et al., 1999). It will envelopes provides insight into the paradox between
the ubiquitous in vitro expression of the receptor on celltherefore be of interest to evaluate the respective impact
of the HTLV envelope on membrane organization, its lines and the apparent restriction of HTLV tropism to
T lymphocytes in vivo. Early after infection, rapid andcytoskeleton-associated cellular partners, such as
GLUT-1 and GLUT1CBP, and other known or yet to be dramatic metabolic alterations associated with de-
creased glucose consumption are likely to occur uponidentified interacting cell surface components.
Because expression of the HTLV receptor is induced expression of the HTLV envelope. It is tempting to pro-
pose that during in vivo infection, HTLV initially spreadsupon glucose starvation, transmission of HTLV may be
more efficient among cells that are locally starved of with a large tropism, but that the vast majority of cells
that are dependent on GLUT-1 activity and concomi-glucose and express high levels of GLUT-1, such as
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D[U-14C]fructose (Amersham). After transfection of Env expressiontantly express the HTLV envelope are rapidly eliminated.
vectors, approximately 2.5  105 293T cells per well were seededIn contrast, resting T lymphocytes that have a low meta-
in 24-well plates. The next day, cells were washed in PBS, incubatedbolic rate and as such are much less dependent on
in serum-free DMEM, washed in serum/glucose-free DMEM, and
glucose uptake, are more likely to tolerate this effect incubated for 20 min in 500 l serum/glucose-free DMEM in the
and survive infection. Furthermore, local imbalances in presence or absence of inhibitors (20M cytochalasin B and 300M
phloretin; Sigma). Uptake was initiated by adding labeled hexoses toglucose uptake, following HTLV infection may lead to
a final concentration of 0.1 mM (2Ci/ml for 2-deoxy-D[1-3H]glucosespecific physiological alterations (Akaoka et al., 2001).
and 0.2 Ci/ml for D[U-14C]fructose and 3-O-[14C]methyl-D-glucose)In this regard, the potential relationship between HTLV-
and cells were incubated for an additional five minutes. Cells wereassociated neuropathologies and the specific depen-
then resuspended in 500 l cold serum/glucose-free DMEM,
dence of neurons on GLUT-1 mediated glucose consump- washed in serum/glucose-free DMEM, and solubilized in 400 l of
tion (De Vivo et al., 1991; Siegel et al., 1998) becomes 0.1% SDS. Three l were used for Bradford normalization, and 3H
or 14C incorporation in the remainder of the samples was counted.particularly relevant.
ImmunoblotsExperimental Procedures
Culture media (10 l) from 293T cells transfected with HTLV RBD,
or lysates from cells overexpressing GLUT-1 or GLUT-3, alone or inCell Culture and Virus Preparations
combination with HTLV-2 RBD, were electrophoresed in SDS–12.5%Human 293T and HeLa cells were grown in DMEM with high glucose
acrylamide gels, transferred and probed with either a peroxidase-(4.5 g/l) and Jurkat T cells were grown in RPMI with 10% fetal bovine
conjugated anti-rabbit immunoglobulin antiserum or mouse mono-serum (FBS) at 37C. Freshly isolated hepatocytes were obtained
clonal antibodies directed against HTLV Env (1C11), HA tag (12CA5),following surgery in accordance with the Hospital Ethics Board as
or actin (C4, ICN), or a rabbit polyclonal serum raised against apublished (Pichard et al., 1990). For glucose starvation experiments,
GLUT-1 carboxy terminal synthetic peptide (generous gift form M.cells were grown in either glucose-free DMEM (Life Technologies)
Mueckler), followed by the corresponding peroxidase-conjugatedor glucose-free RPMI (Dutscher) with 10% dialyzed FBS (Life Tech-
anti-immunoglobulin antiserum. Proteins were visualized using thenologies) and glucose (1 g/l) was supplemented when indicated.
ECLplus kit (Amersham).Replication-defective LacZ retroviral vector was pseudotyped with
either HTLV or A-MLV envelopes as previously described (Kim et
al., 2003b). Coimmunoprecipitation Assay
293T cells were transfected with the various envelope expression
vectors, alone or in combination with the GLUT-1 expression vector.Expression Vectors and siRNAs
Twenty-four hours following transfection, cells were lysed in BrijFull-length envelope expression vectors have been described else-
buffer (1% Brij97, 150 mM NaCl, 20 mM Tris [pH 7.5], and 5 mMwhere (Denesvre et al., 1995 1996; Rosenberg et al., 1998). The
EDTA); 10% of the lysate was used for immunoblots of total proteinchimeric HTLV/MLV Env, H183FEnv, was obtained by replacing the
extracts, while 90% of the lysate was immunoprecipitated with aga-first 269 amino acid residues of the F-MLV Env with the 183 amino-
rose beads coupled to goat anti-rabbit IgG immunoglobulins (Sigma)terminal residues of the HTLV-1 Env. H1RBD, H2RBD, and ARBD comprise
for 4 hr at 4C. Beads were washed four times with Brij buffer,the first 215 aa, 178 aa, and 397 aa of the HTLV-1, HTLV-2, and
denatured in loading buffer, and processed for immunobloting.A-MLV SU, respectively, fused to either a carboxy-terminal rabbit
immunoglobulin Fc (rFc) tag or to the enhanced green fluorescence
protein (EGFP) coding sequence. Construction of the chimeric enve- Binding Assays
lope as well as wild-type and mutant truncated envelope expression Binding assays were carried out as previously described (Manel et
vectors will be detailed elsewhere. Human Glut-1 and Glut-3 cDNA al., 2003). Briefly, 5  105 cells were washed with PBA (PBS con-
were amplified by PCR from the pLib HeLa cDNA library (Clontech) taining 1% bovine serum albumin [BSA] and 0.1% sodium azide),
from the first AUG to the last codon before the termination codon, incubated with 300 l of control, HRBD, or ARBD supernatants for 30
and individually inserted into pCHIX, a modified version of the pCSI min at 37C, washed, and labeled for 30 min on ice with an FITC-
vector (Battini et al., 1999) that includes a C-terminal factor Xa conjugated sheep anti-rFc antibody (1:500 dilution; Sigma). Cells
cleavage site, and the hemagglutinin (HA) and histidine tags. Glut-1 were immediately analyzed on a FACSCalibur (Becton Dickinson).
and Glut-3 cDNA were also inserted into a modified pCSI vector When indicated, cytochalasin B (20 M; Sigma) was added to cells
that includes a DsRed2 C-terminal tag. Similarly, human CD147 was for 1 hr prior to binding analyses.
amplified from 293T total RNA and inserted into pCHIX. The rat
MCT1 expression vector was a gift from J. Mercier and G. Py and Infections
the VSVG-tagged human PiT-2 expression vector was a gift from 105 293T target cells were treated as follows prior to infection: (1)
J.-M. Heard (Rodrigues and Heard, 1999). The sequences of the incubation for 30 min with 20 M cytochalasin B, (2) transfection
three synthetic annealed siRNAs complementary to the GLUT-1 with either the interfering H2RBD or pCDNA in the presence or absence
3UTR, and which are not present in the GLUT-1 expression vector, of GLUT-1 or GLUT-3 expression vectors, or (3) transfection with
are UGAUGUCCAGAAGAAUAUUTT, AAUAUUCUUCUGGACAUCATT, 20 pmol of an equimolar mixture of three siRNAs complementary
and UAUUAAAUACAGACACUAATT (Eurogentec, plus strand indi- to the endogenous GLUT-1 3UTR in the presence or absence of
cated). GLUT-1 or GLUT-3 cDNA expression vectors. Infections were car-
ried out with serial dilutions of LacZ retroviral vectors pseudotyped
Envelope Expression and Metabolic Measurements with either HTLV-2 or A-MLV envelopes. The following day, fresh
293T cells were transfected with the envelope expression vectors medium supplemented with fructose (5 g/l) was added. Twenty-four
using the calcium phosphate method. After an overnight transfec- hours later, LacZ expression was monitored by X-Gal staining.
tion, cells were washed in phosphate-buffered saline (PBS) and
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